Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells 274,297 Shares of Stock
by Jessica Moore · The Cerbat GemDyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Jason Rhodes sold 274,297 shares of the stock in a transaction that occurred on Tuesday, April 21st. The shares were sold at an average price of $19.52, for a total value of $5,354,277.44. Following the sale, the director directly owned 13,148 shares of the company’s stock, valued at approximately $256,648.96. This trade represents a 95.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Dyne Therapeutics Trading Up 2.4%
Dyne Therapeutics stock traded up $0.46 during trading hours on Wednesday, reaching $19.67. The stock had a trading volume of 2,148,963 shares, compared to its average volume of 2,169,838. The company has a fifty day simple moving average of $17.52 and a 200-day simple moving average of $18.35. Dyne Therapeutics, Inc. has a 52 week low of $8.06 and a 52 week high of $25.00. The stock has a market cap of $3.25 billion, a PE ratio of -5.56 and a beta of 1.29. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its earnings results on Monday, March 2nd. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.02). Analysts forecast that Dyne Therapeutics, Inc. will post -2.94 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently modified their holdings of DYN. Pictet Asset Management Holding SA lifted its holdings in shares of Dyne Therapeutics by 49.4% during the first quarter. Pictet Asset Management Holding SA now owns 19,372 shares of the company’s stock valued at $351,000 after purchasing an additional 6,409 shares in the last quarter. Wasatch Advisors LP increased its holdings in Dyne Therapeutics by 9.0% in the 1st quarter. Wasatch Advisors LP now owns 443,668 shares of the company’s stock worth $8,044,000 after buying an additional 36,708 shares in the last quarter. Hilton Head Capital Partners LLC purchased a new position in Dyne Therapeutics in the 1st quarter worth about $26,000. Rockefeller Capital Management L.P. lifted its stake in Dyne Therapeutics by 67.1% during the 4th quarter. Rockefeller Capital Management L.P. now owns 14,268 shares of the company’s stock valued at $279,000 after acquiring an additional 5,730 shares during the period. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Dyne Therapeutics during the 4th quarter valued at about $1,373,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on DYN. JPMorgan Chase & Co. lowered their target price on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a research note on Tuesday, January 20th. Jefferies Financial Group reissued a “buy” rating on shares of Dyne Therapeutics in a research report on Monday, March 9th. Morgan Stanley dropped their price objective on shares of Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research note on Monday, March 2nd. HC Wainwright decreased their target price on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, March 3rd. Finally, Wall Street Zen lowered shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, December 28th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $35.14.
About Dyne Therapeutics
Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.
Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.